Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Kronos Bio (KRON) Stock Price & Analysis
163 Followers
KRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $2.29
Previous Close$1.02
Volume299.88K
Average Volume (3M)389.06K
Market Cap
$61.30M
Enterprise Value-$83.43M
Total Cash (Recent Filing)$173.00M
Total Debt (Recent Filing)$28.27M
Price to Earnings (P/E)-0.5
Beta1.50
Next Earnings
May 08, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding60,095,013
10 Day Avg. Volume821,012
30 Day Avg. Volume389,059
Standard Deviation0.19
R-Squared0.26
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.39
Price to Sales (P/S)9.73
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-13.21
Enterprise Value/Gross Profit-13.24
Enterprise Value/Ebitda0.80
Forecast
1Y Price Target
$4.13Price Target Upside304.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Kronos Bio News
PremiumCompany Announcements
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
PremiumCompany Announcements
Kronos Bio Implements Workforce Reduction to Extend Financial RunwayBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsKB-0742 showed a disease control rate of 48% in higher dose cohorts and one partial response in a myxoid liposarcoma patient, indicating on-mechanism clinical activity.
Drug Development ProgressKronos is reallocating resources toward KB-0742, expressing hope for increased efficacy during upcoming updates for dose expansion cohorts.
New Therapy AnnouncementKronos has unveiled KB-9558, a potential new therapy for multiple myeloma, with IND-enabling studies set to complete this year.
Bears Say
Clinical Trial SetbacksKronos discontinues the Phase II portion of the trial for lanraplenib due to insufficient complete responses in patients.
Regulatory And Development RisksThere is a risk that Kronos may fail to develop KB-0742 on schedule or receive the necessary regulatory approvals.
Safety ConcernsSeveral patients experienced severe adverse events related to KB-0742, raising concerns about the drug's safety profile.
---
Ownership Overview
51.09% Insiders
13.44% Mutual Funds
10.77% Other Institutional Investors
24.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.73 and its highest was $2.29 in the past 12 months.
What is Kronos Bio’s market cap?
Currently, no data Available
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is May 08, 2024 which is in 3 days.
How were Kronos Bio’s earnings last quarter?
Kronos Bio released its earnings results on Mar 21, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.095.
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Undervalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate is -$0.45.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,094,410 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Kronos Bio reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of Kronos Bio?
Among the largest hedge funds holding Kronos Bio’s share is Omega Fund Management, LLC. It holds Kronos Bio’s shares valued at 5M.
---
Kronos Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (304.90% Upside)
$4.13 (304.90% Upside)
Hedge Fund Trend
Decreased
By 173.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.28%
12-Months-Change
Fundamentals
Return on Equity
-55.84%
Trailing 12-Months
Asset Growth
-27.69%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Months Forecast
Average Price Target
$4.13
▲(304.90% Upside)
Technical Analysis
RAPT Therapeutics
―
Arvinas Holding Company
―
Corvus Pharmaceuticals
―
Puma Biotechnology
―
Best Analysts Covering KRON
1 Year
1 Year Success Rate
1/17 ratings generated profit
1 Year Average Return
-44.70%
reiterated a buy rating 2 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -44.70% per trade.
---